- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03770702
Statins and ARBs on Rheumatoid Activity
December 7, 2018 updated by: Sherief Abd-Elsalam
Investigational and Comparative Study Between the Anti-inflammatory Effectof Both Angiotensin Reeptor Blockers and Statins on Rheumatoid Arthritis Disease Activity on Egyptian Patients
Investigational and comparative study between the anti-inflammatory effectof both angiotensin reeptor blockers and statins on rheumatoid arthritis disease activity on Egyptian patients
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study aims at ivestigating and comparing the anti-inflammatory effectof both angiotensin reeptor blockers and statins on rheumatoid arthritis disease activity on Egyptian patients
Study Type
Interventional
Enrollment (Anticipated)
45
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tanta, Egypt, 35111
- Recruiting
- Sherief Abd-Elsalam
-
Contact:
- Ahmed El-Abd, Msc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Rheumatoid arthritis.
Exclusion Criteria:
- Pregnant or lactating
- Hepatic or renal impairment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control group
No intervention
|
|
Active Comparator: Angiotensin receptor blockers
ARB ( Angiotensin receptor blockers) + Traditional therpy.
|
Candesartan
Other Names:
|
Active Comparator: Statins
Statin + Traditional therapy.
|
Atorvastatin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in disease activity score
Time Frame: 6 months
|
DAS28-ESR
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sahar K Hegazy, Prof, Head of clinical Pharmacy Department
- Study Director: Tarek M Mostafa, Prof, Prof of Clinical Pharmacy
- Study Chair: Emad M Elshebini, MD, Rheumatology Dept. - Menoufia University
- Study Chair: Ahmed HM El-Abd, Msc, Clinical pharmacy Department-Tanta University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2018
Primary Completion (Anticipated)
December 1, 2025
Study Completion (Anticipated)
December 1, 2026
Study Registration Dates
First Submitted
December 7, 2018
First Submitted That Met QC Criteria
December 7, 2018
First Posted (Actual)
December 10, 2018
Study Record Updates
Last Update Posted (Actual)
December 10, 2018
Last Update Submitted That Met QC Criteria
December 7, 2018
Last Verified
December 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Rheumatoid
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on Angiotensin receptor blockers
-
Institut universitaire de cardiologie et de pneumologie...Odense University HospitalRecruiting
-
ADARx Pharmaceuticals, Inc.ADARx Australia Pty LtdRecruitingHypertension | Hypertension,EssentialAustralia
-
Shiga UniversityCompleted
-
The George InstituteCompletedCOVID-19 | Coronavirus Disease 2019Australia, India
-
IlDong Pharmaceutical Co LtdUnknownHealthy VolunteersKorea, Republic of
-
Medical University of LodzCompletedUric Acid Concentration, Serum, Quantitative Trait Locus 7
-
NovartisCompletedHypertensionSwitzerland
-
NovartisCompleted
-
Unidad de Investigacion Medica en Enfermedades...Completed